Wilmington Savings Fund Society FSB Acquires Shares of 218 Krystal Biotech, Inc. (NASDAQ:KRYS)

Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the third quarter, HoldingsChannel.com reports. The institutional investor purchased 218 shares of the company’s stock, valued at approximately $40,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Summit Trail Advisors LLC bought a new position in shares of Krystal Biotech during the third quarter valued at approximately $1,893,000. Swiss National Bank increased its stake in Krystal Biotech by 8.0% in the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after purchasing an additional 2,900 shares during the period. Sei Investments Co. lifted its position in shares of Krystal Biotech by 18.9% during the second quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock worth $7,367,000 after purchasing an additional 6,363 shares during the last quarter. Shaker Investments LLC OH purchased a new stake in shares of Krystal Biotech during the third quarter valued at $532,000. Finally, Citigroup Inc. grew its holdings in shares of Krystal Biotech by 65.4% in the third quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock worth $6,386,000 after purchasing an additional 13,874 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Trading Up 2.5 %

Shares of NASDAQ:KRYS opened at $164.83 on Monday. The company has a market capitalization of $4.74 billion, a PE ratio of 93.12 and a beta of 0.80. Krystal Biotech, Inc. has a 12-month low of $107.50 and a 12-month high of $219.34. The business’s fifty day simple moving average is $180.18 and its 200-day simple moving average is $185.29.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same period in the previous year, the company posted ($0.67) earnings per share. The firm’s revenue was up 879.9% on a year-over-year basis. Research analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on KRYS shares. Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Chardan Capital reissued a “buy” rating and issued a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $206.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).